Hims & Hers: I See No New Red Flags
Hims & Hers stock is crashing in pre-market trading, down about 14%, after reporting a disastrous Q1 and an upbeat Q2 outlook. We don't find Q1 weakness surprising due to the Novo deal timing and tough Y/Y comparison with 1Q25. We understand that investors wanted more from print after the stock doubled from $14 lows, but we remain confident that, post-expectation reset, HIMS will be better positioned to beat expectations.
U.S.-Iran Ceasefire on "Life Support," HIMS & ASTS Earnings Sell-Off
The U.S.-Iran ceasefire is on "life support," according to President Trump, causing stocks to slide and crude oil to climb in the overnight hours. Kevin Green explains how the geopolitical headlines come head-to-head with the red-hot tech rally.
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Hims & Hers Health Q1 Earnings Call Highlights
Hims & Hers Health NYSE: HIMS reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company's weight-loss business is creating short-term margin pressure and volatility in GAAP results.
Hims & Hers Health: Mixed Q1 2026 Is Not A Thesis Breaker
Hims & Hers Health, Inc. remains a Buy, with a solid bottom forming despite recent margin and revenue challenges. HIMS is pivoting from compounded GLP-1s to branded partnerships with NVO and LLY, impacting near-term margins but reducing legal risk. Q1 2026 saw revenue miss and margin compression, but management raised full-year revenue guidance and expects margin expansion in H2.
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Misses Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.2 per share a year ago.
Hims & Hers Stock Sinks. Why Earnings Offered Wall Street A Big Surprise.
Hims & Hers shares are falling after reporting disappointing first-quarter earnings results.
Can Platform Expansion Support Hims & Hers Stock Before Q1 Earnings?
HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and GLP-1 scrutiny linger.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS) closed at $26.37 in the latest trading session, marking a -3.79% move from the prior day.
Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now?
Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
Hims & Hers Health, Inc. (HIMS) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
